TREATMENT FOR DUPUYTREN'S DISEASE

• US 20190322733A1
• Filed: 04/30/2019
• Published: 10/24/2019
• Est. Priority Date: 10/30/2010
• Status: Active Grant

• Current Assignee: Oxford University Innovation Limited (University of Oxford)
• Original Assignee: Oxford University Innovation Limited (University of Oxford)
• Inventors: Nanchahal, Jagdeep, Midwood, Kim Suzanne
• Granted Patent: US 10,669,334 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Musculoskeletal fibroproliferative disorders, such as Dupuytren'"'"'s disease may be treated by administering locally a TNF-α antagonist. TNF-α antagonists find particular utility in inhibiting the progression of early disease state Dupuytren'"'"'s disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren'"'"'s disease and, in particular inhibiting recurrence.

Claims

1-19. -19. (canceled)

20. A method for treating a patient with early disease state periarticular fibrosis or adhesion comprising injecting an amount of a TNF-α

antagonist effective to treat the patient directly at the site of the early disease state periarticular fibrosis or adhesion, so as to treat the patient.

48. A method of claim 20, wherein the TNF-α

antagonist is selected from one or more of Infliximab, Adalimumab, Certolizumab pegol, Golimumab or Etanercept.

50. A method of claim 20, wherein the TNF-α

antagonist is Infliximab.

51. A method of claim 20, wherein the TNF-α

antagonist is Adalimumab.

52. A method of claim 20, wherein the TNF-α

antagonist is Certolizumab pegol.

53. A method of claim 20, wherein the TNF-α

antagonist is Golimumab.

54. A method of claim 20, wherein the TNF-α

antagonist is Etanercept.

55. A method of claim 20 further comprising administering an extracellular matrix degradation, depletion or cleavage agent.

56. A method of claim 55, wherein the extracellular matrix degradation, depletion or cleavage agent is a matrix metalloproteinase and/or a collagenase.

57. A method of claim 55, wherein the extracellular matrix degradation, depletion or cleavage agent is administered locally to the disease site.

21-47. -47. (canceled)

49. A method of claim 49, wherein the TNF-α

antagonist is an anti-TNF-α

antibody.